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ABSTRACT
Aims: Vitamin D receptor (VDR) expression has been associated with survival 
in several cancer sites. This study aims to evaluate the association between VDR 
expression and prognosis in oesophageal adenocarcinoma patients.
Results: During a median of 2.5 (maximum 9) years of follow-up, 75 patients 
died. In analysis adjusted for confounders, higher VDR expression was associated 
with an improved overall survival (HR 0.49 95% CI 0.25–0.96) and disease-specific 
survival (HR 0.50 95% CI 0.26–0.99), when comparing the highest with the lowest 
tertile of expression. These associations were strongest in sensitivity analysis 
restricted to junctional tumours. 
Conclusions: This study is the first to demonstrate that patients with higher 
VDR expression in oesophageal adenocarcinoma have a more favourable prognosis. 
Further work is needed to validate these findings, and to define the role of VDR in the 
aetiology, progression and management of oesophageal adenocarcinoma. 
Methods: Oesophageal adenocarcinoma specimens and clinical data were 
collected from 130 patients treated with neo-adjuvant chemotherapy prior to surgical 
resection at the Northern Ireland Cancer Centre between 2004 and 2012. Tissue 
microarrays were created and immunohistochemical staining for VDR was performed 
on triplicate tumour cores from each resection specimen. Cox proportional hazards 
models were applied to evaluate associations between VDR, according to tertiles of 
expression, and survival outcomes. 
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INTRODUCTION
Oesophageal cancer causes 400,000 deaths 
worldwide each year and ranks as the sixth most common 
cause of cancer mortality [1]. Neo-adjuvant therapy has 
somewhat improved prognosis, however 5-year survival 
rates for this malignancy still only range between 10% 
and 18% in Western settings [2, 3]. These low figures are 
partially related to more than 30% of oesophageal cancer 
patients having metastatic disease at first presentation [2]. 
Even in those patients with localised disease who have 
undergone attempted curative surgery, the 5-year survival 
is still as low as 41% [2]. In addition to early detection 
initiatives, there is a need to identify actionable, prognostic 
biomarkers to help predict patient outcome and also to 
identify novel therapeutic targets.  
The vitamin D receptor (VDR) exerts its biological 
influence by binding with circulating vitamin D, and 
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thereby contributes to the regulation of apoptosis and cell 
differentiation, and suppression of cancer cell proliferation 
[4–6]. In-vitro studies within colorectal cancer cell lines 
have demonstrated that cells with high VDR expression 
tend to be well differentiated and are biologically 
favourable, whereas cell lines with low VDR expression 
demonstrated aggressive features with higher metastatic 
potential [7]. These findings have been translated in 
clinical studies which have shown that high VDR 
expression has been associated with increased survival 
in colorectal, pancreatic and breast cancer, cutaneous 
melanoma, urothelial bladder cancer and oesophageal 
squamous cell carcinoma [8–13]. 
To date, there has been little research investigating 
VDR expression and oesophageal adenocarcinoma 
outcomes. However, several published papers have 
reported differences in VDR expression when comparing 
native, pre-malignant and oesophageal adenocarcinoma 
tissue in cross-sectional analyses from different patients 
[14, 15]. One study reported no VDR staining in normal 
oesophageal squamous mucosa, whereas Barrett’s 
mucosa and low grade dysplasia had strongly positive 
VDR staining (95% and 100%, respectively), which 
then decreased slightly in tissue from patients with 
adenocarcinoma (79%) [14]. This study is discussed in 
depth in the discussion section. Similar findings were 
observed in a small study which assessed VDR expression 
in tumour, adjacent normal and Barrett’s mucosa, from 
five oesophageal adenocarcinoma resection specimens 
[15]. Collectively, these findings suggest that VDR 
expression only features in oesophageal cells after they 
have undergone metaplastic transition, but it is unclear if 
this is a cause-or-effect role.  The implications of VDR 
expression on further progression of columnar epithelium 
to oesophageal adenocarcinoma, and prognosis after 
adenocarcinoma development remains unclear. 
To date, only one study has investigated the 
association between VDR expression and oesophageal 
adenocarcinoma outcomes in 116 patients. In this patient 
cohort  from the University of Rochester, New York, no 
significant difference in outcome in those patients with 
high compared to low VDR expression was seen [14].   
This study aims to expand on this limited evidence, 
to investigate the association between VDR expression 
and prognosis in oesophageal adenocarcinoma patients 
who have undergone neoadjuvant chemotherapy and 
surgical resection.
RESULTS
Patient demographics and tumour 
characteristics 
Of the total 130 oesophageal adenocarcinoma 
patients in this study, 78% were male and 22% were 
female. The majority of tumours were located at the gastro-
oesophageal junction (84.6%), with Siewert 1 tumours the 
most common (50.8%), followed by Siewert 2 (25.4%) and 
Siewert 3 (8.5%).
Table 1 presents the patient demographics and tumour 
characteristics across tertiles of maximum VDR expression. 
There was no difference by patient sex, age at diagnosis, year 
of diagnosis, smoking, or alcohol status according to tertiles 
of VDR expression. There were fewer Siewert 1 tumours 
in the highest compared with the lowest tertile of VDR 
expression (p = 0.04). There was also a difference in T-stage 
(p = 0.04) according to tertiles of VDR expression, 
although this mostly reflect small numbers in some 
categories. There was no difference in lymphovascular 
invasion, circumferential resection margin status, tumour 
differentiation or surgical nodal status according to tertiles 
of VDR expression. 
Survival analysis
There were 75 patients who had died during a 
maximum of 9 (median 2.5) years of follow-up. As 
shown in Table 2, in unadjusted analysis, a higher VDR 
expression showed a trend towards significance with an 
improved survival. In adjusted analysis, a dose-response 
association between higher VDR expression and improved 
overall survival became apparent. In patients with tumour 
VDR expression in the middle tertile, there was a 40% 
non-significant reduced risk of death (HR 0.60 95% CI 
0.33–1.09; p = 0.09) and those in the highest tertile had 
a 51% significantly lower risk of death (HR 0.49 95% CI 
0.25–0.96; p = 0.04), compared with the lowest VDR 
expression category. This association was not as apparent 
in analysis evaluating high and low VDR expression as 
determined by the median cut-off; higher VDR expression 
was associated with an 18% non-significant reduced risk 
of death (HR 0.82 95% CI 0.48–1.38; p = 0.45) for high 
VDR expression compared with the low VDR expression 
group. Very similar patterns of results were observed in 
cancer-specific survival analysis (Table 2). 
Sensitivity analysis 
Table 3 outlines sensitivity analysis restricted to 
junctional tumours.  As with the main analysis, higher 
VDR expression was associated with improved overall 
survival and cancer-specific survival, and the magnitude 
of associations were strengthened. Patients with VDR 
expression in the highest tertile had a significant 56% 
reduction in all-cause mortality (HR 0.44 95% CI 
0.22–0.99), with similar reductions in cancer-specific 
mortality, although statistical significance was slightly 
attenuated (HR 0.47 95% CI 0.21–1.02) compared to 
patients with the lowest VDR expression tumour cores. 
Secondary analysis in which all above outcomes 
were evaluated for median, rather than maximum, VDR 
expression largely showed similar results that were 
attenuated in statistical significance (data not shown). 
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Table 1: Patient demographics and tumour characteristics according to tertiles of maximum VDR expression
Total number
n = 130
Tertile 1
H score <120
n = 48
Tertile 2
H score 120–240
n = 47
Tertile 3
H score >240
n = 35
P-value
Sex
Male 101 (77.7) 34 (70.8) 38 (80.9) 29 (82.9)
Female 29 (22.3) 14 (29.2) 9 (19.2) 6 (17.1) 0.35
Age at diagnosis (years)
<50 14 (10.8) 6 (12.5) 4 (8.5) 4 (11.4)
50–59 25 (19.2) 7 (14.6) 11 (23.4) 7 (20.0) 0.79
60–79 61 (46.9) 26 (54.2) 21 (44.7) 14 (40.0)
≥80 30 (23.1) 9 (18.8) 11 (23.4) 10 (28.6)
Smoking status
Never smoker 34 (26.2) 12 (25) 11 (23.4) 11 (31.4)
Former smoker 48 (36.9)  18 (37.5) 17 (36.7) 13 (37.4)
Current smoker   31 (23.9) 11 (22.9) 14 (29.8) 6 (17.1) 0.90
Unknown 17 (13.1) 7 (14.6) 5 (10.64) 5 (14.3)
Alcohol 
Never drinker 41 (31.5) 12 (25.0) 15 (31.9) 14 (40.0)
Ever 69 (53.1) 27 (56.3) 26 (55.3) 16 (45.7) 0.64
Unknown 20 (15.4) 9 (18.8) 6 (12.8) 5 (14.3)
Primary site
Lower third 20 (15.4) 6 (12.5) 6 (12.8) 8 (22.9)
Gastro-oesophageal  
junction
110 (84.6) 42 (87.5) 41 (87.2) 27 (77.1) 0.36
Siewert classification   
1 66 (50.8) 24 (50) 31 (66) 11 (31.4)
2 33 (25.4) 16 (33.3) 6 (12.8) 11 (31.4) 0.04
3 11 (8.5) 2 (4.2) 4 (8.5) 5 (14.3)
PET responder
No 43 (33.1) 16 (33.3) 14 (29.8) 13 (37.1)
Yes 57 (43.9) 20 (41.7) 22 (46.8) 15 (42.9) 0.95
Unknown 32 (23.1) 12 (25.0) 11 (23.4) 7 (20.0)
Lymphatic vascular 
invasion
No 40 (30.8) 15 (31.3) 13 (27.7) 12 (34.3)
Yes 90 (69.2) 33 (66.7) 34 (72.3) 23 (65.7) 0.81
Circumferential resection 
margin status
Negative 73 (56.1) 26 (54.2) 27 (57.5) 20 (57.1)
Positive 57 (43.9) 22 (45.8) 20 (42.6) 15 (42.9) 0.94
Differentiation
Well or Moderate 52 (40.0) 22 (45.8) 17 (36.2) 13 (37.1)
Moderate-Poor or Poor 78 (60.0) 26 (54.2) 30 (63.8) 22 (62.9) 0.58
Surgical T stage
1 11 (8.5) 6 (12.5) 1 (2.1) 4 (11.4)
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DISCUSSION
This study is the first to demonstrate a significant, 
dose-response, association between higher VDR 
expression and improved survival in patients with 
oesophageal adenocarcinoma. Sensitivity analysis also 
demonstrated that the association between higher VDR 
expression and improved survival was particularly evident 
in patients with oesophago-gastric junctional tumours.
These findings contrast with those from the only 
other published study to have considered the impact 
of VDR expression on oesophageal cancer survival. 
In a study of 116 patients in the USA, no significant 
difference in overall survival (21 months in high VDR 
expression versus 20 months in low VDR expression) was 
demonstrated between groups with high and low VDR 
expression (p = 0.99) [14]. There are multiple differences 
in that study’s design compared with ours that may 
account for the conflicting results. Firstly, in our study, all 
patients underwent neoadjuvant treatment prior to surgical 
resection, whilst in the aforementioned study all patients 
had surgical resection without neo-adjuvant therapy 
[14]. Limited research is available to explore the impact 
of neoadjuvant treatment upon VDR expression of the 
primary tumour, although one small study in 15 patients 
found those with higher VDR expression were less likely 
to respond to treatment, indicating a potential interaction 
[16]. However, the authors accepted that these results 
could be simply due to chance [16]. Secondly, the methods 
of scoring and analysing the VDR expression differed in 
that there was only one sample taken for each patient and 
there was considered to be a high expression of VDR if 
10% or more of cells stained with an intensity score of 2+ 
or 3+ [14]. This would be the equivalent of an H-score of 
20 or 30 in our study to divide patients into high and low 
expression, whereas our lowest tertile reflected an H-score 
of less than 120. Our methods also involved scoring three 
cores rather than one from each tumour specimen, which 
2 25 (19.2) 4 (8.3) 15 (31.9) 6 (17.1)
3 89 (68.5) 36 (75) 28 (59.6) 25 (71.4) 0.04
4 5 (3.9) 2 (4.2) 3 (6.4) 0 (0)
Surgical N stage
0 44 (33.9) 16 (33.3) 16 (34.0) 12 (34.3)
1 27 (20.8) 11 (22.9) 10 (21.3) 6 (17.1)
2 29 (22.3) 9 (18.8) 13 (27.7) 7 (20.0) 0.86
3 30 (23.1) 12 (25.0) 8 (17.0) 11 (28.6)
Abbreviations: PET = Positive emission tomography scan; T-stage = Tumour stage; N stage = Nodal stage.
Table 2: Oesophageal adenocarcinoma survival outcomes according to Vitamin D receptor expression
Dead
n = 75
Alive 
n = 55
Unadjusted 
Hazard ratio 
(95% CI)
P-value
Adjusted 
Hazard ratioa 
(95% CI) 
P-value
Overall survival
Low (<median) 39 23 1.00 1.00
High (≥median) 36 32 0.71 (0.45–1.13) 0.15 0.82 (0.48–1.38) 0.45
Tertile 1 (<120) 24 18 1.00 1.00
Tertile 2 (120–240) 31 17 0.84 (0.5–1.41) 0.51 0.60 (0.33–1.09) 0.09
Tertile 3 (>240) 20 20 0.65 (0.36–1.20) 0.17 0.49 (0.25–0.96) 0.04
Cancer-specific survivalb
Low (<median) 37 23 1.00 1.00
High (≥median) 33 32 0.72 (0.45–1.15) 0.17 0.83 (0.48–1.42) 0.49
Tertile 1 (<120) 28 19 1.00 1.00
Tertile 2 (120–240) 26 18 0.80 (0.47–1.37) 0.42 0.55 (0.29–1.04) 0.06
Tertile 3 (>240) 16 18 0.69 (0.37–1.27) 0.23 0.50 (0.26–0.99) 0.05
Abbreviations: CI = Confidence Intervals. 
aVariables included in the adjusted analysis were age at diagnosis, gender, tumour nodal status, circumferential resection 
margin, tumour differentiation, lymphovascular invasion, smoking status and tumour location.
bThis analysis included 125 patients as 5 had died due to other causes.
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reduces the likelihood of sampling bias. Thirdly, there 
may be underlying differences in the population studied 
(Northern Ireland and the USA) and fourthly, this study 
used a different antibody to stain the specimens. All of 
these factors may account somewhat for the difference in 
findings. 
Although there is limited research looking at 
the impact of high VDR expression in oesophageal 
adenocarcinoma outcomes, there are multiple other clinical 
studies which look at the impact of high VDR expression 
on survival in patients with other cancer sites. Some, but 
not all, studies within colorectal cancer patients have 
demonstrated that higher VDR expression is associated 
with improved survival [8, 17, 18]. A single study looking 
at the impact of VDR expression on survival in pancreatic 
adenocarcinoma performed in a Chinese population of 61 
patients found that patients with high VDR expression 
survived longer than those with low or no VDR expression 
[9]. Similar results were found in a single study looking 
at the impact of VDR expression in cholangiocarcinoma 
in a Thai study of 111 patients. Patients with no VDR 
expression had a 2-fold higher increased risk of death 
than in patients whose tumours expressed VDR (HR 2.00 
95% CI 1.07–3.76) [19]. Studies in melanoma skin cancer, 
breast cancer, oesophageal squamous cell carcinoma and 
urothelial bladder cancer have also found similar findings 
with improved overall survival and progression free 
survival in patients with higher VDR expression within 
the tumour tissue [11–12]. 
Another interesting feature of previous studies 
in other cancer sites was that higher VDR expression 
was more frequently observed in well differentiated 
tumours compared to poorly differentiated tumours 
in colorectal cancer, pancreatic adenocarcinoma and 
cholangiocarcinoma [8, 9, 19]. This corroborates similar 
findings in a previous study by Trowbridge et al. in tissue 
from 15 oesophageal adenocarcinoma patients [16]. In our 
study however, there was no association between tumour 
grade and VDR expression, and adjustment for grade 
within our survival analysis did not affect our results. 
When we performed sensitivity analysis for 
junctional tumours only, there was a greater magnitude 
of association between VDR expression and overall 
survival and disease-specific survival, although statistical 
significance was slightly attenuated for the latter. Previous 
findings suggest that VDR expression only features in 
oesophageal cells after they have undergone metaplastic 
transition, but it is unclear if this is a cause-or-effect role 
[15, 20]. Our findings in the sensitivity analysis may 
therefore arise due to a difference in VDR expression 
between tumour sites. This theory is supported by the fact 
that junctional tumours can arise from oesophageal tissue 
or gastric tissue and these tissues may differ biologically 
in both their normal state and pre-malignant state. 
Evidence from our study demonstrates for the first 
time that any association between circulating vitamin 
D levels and oesophageal adenocarcinoma outcomes, 
mediated by VDR expression, may be biologically plausible. 
VDR are activated when they combine with vitamin D3, the 
active form of vitamin D. This subsequently combines with 
the retinoid x receptor which can then promote or suppress 
hallmarks of tumorigenesis [5, 6]. Indeed, a cell-line study 
has demonstrated that VDR activation regulates apoptosis 
and cell differentiation, and suppresses tumour proliferation 
[4]. However, further studies that incorporate assessment 
of serum 25-hydroxyvitamin D status in addition to 
tumour VDR expression in patients with oesophageal 
adenocarcinoma are required to corroborate this hypothesis.
Table 3: Sensitivity analysis of oesophageal adenocarcinoma survival outcomes according to Vitamin D receptor 
expression, restricted to junctional tumours only
Dead
n = 67
Alive 
n = 43
Adjusted 
Hazard ratioa 
(95% CI) 
P-value
Overall survival
Tertile 1 (<120) 25 17 1.00
Tertile 2 (120–240) 26 15 0.50 (0.26–0.97) 0.04
Tertile 3 (>240) 16 11 0.46 (0.21–0.98) 0.04
Cancer-specific survivalb
Tertile 1 (<120) 24 17 1.00
Tertile 2 (120–240) 23 15 0.44 (0.21–0.89) 0.02
Tertile 3 (>240) 15 11 0.47 (0.22–1.02) 0.05
Abbreviations: CI = Confidence Intervals. 
aVariables included in the adjusted analysis were age at diagnosis, gender, tumour nodal status, circumferential resection 
margin, tumour differentiation, lymphovascular invasion, and smoking status.
bThis analysis included 105 patients as opposed to 110 patients as in the overall survival analysis as 5 had died due to other 
causes.
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Research into the impact of vitamin D with 
respect to oesophageal adenocarcinoma risk is highly 
controversial, with observational studies having reported 
null results, decreased risks, or indeed increased risks 
of oesophageal adenocarcinoma in patients with higher 
levels of vitamin D intake or status [21–24]. No clear 
associations for circulating vitamin D levels and prognosis 
after a diagnosis of oesophageal cancer were identified 
in a European cohort study, although that included only 
74 adenocarcinoma patients [25]. Our study provides 
some evidence that VDR is associated with oesophageal 
adenocarcinoma outcomes, and therefore indirect evidence 
of a biological role for vitamin D.
One observational study has investigated the 
impact of post-operative vitamin D supplementation in 
patients having undergone surgical resection for their 
oesophageal squamous cell carcinoma [26]. There were 
280 patients with oesophageal squamous cell carcinoma 
and of these there were 49 patients who took daily vitamin 
D supplements of between 200–400 international units 
daily [26]. Although vitamin D supplement use was 
not associated with improved overall survival, it was 
associated with a 39% reduction in disease recurrence in 
adjusted analysis (HR 0.61 95% CI 0.38–0.98) [26].  This 
demonstrates the role that vitamin D may play in the post-
operative phase in oesophageal squamous cell carcinoma. 
Theoretically, if VDR levels impact on survival 
and vitamin D activates the VDR, then vitamin D may 
play a role in the neo-adjuvant treatment phase or even 
in the chemo-preventative setting [3, 27]. This hypothesis 
is supported by findings in other cancers with in-vivo 
studies in colorectal, pancreatic and gastric cancer having 
shown 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 
and vitamin D analogues to decrease cancer cell growth 
[28–30]. Furthermore, results in animal models have been 
encouraging as vitamin D3 has been shown to decrease 
both pre-cancerous and cancerous lesions in gastric cancer 
in rats [31]. 
This study has several strengths, including being 
the first study to identify VDR as potential biomarker 
to predict outcomes in oesophageal adenocarcinoma, 
and only the second study to investigate this association. 
Furthermore, our study was performed in a population 
which has low exposure to vitamin D and a high incidence 
of oesophageal adenocarcinoma [2, 32]. Survival remains 
poor in this disease with limited treatment options and 
this study enables hypothesis generation around the role 
of vitamin D analogues in the management of oesophageal 
adenocarcinoma [33].  
The main limitation of this study is the relatively 
small sample size, although our cohort size of 130 patients 
is typical of this relatively rare disease site. All patients 
had surgically resectable disease, therefore this cohort 
represents patients with more favourable prognosis, and 
we cannot deduce if VDR expression impacts upon the 
outcome in patients with more advanced disease. Future 
studies should aim to evaluate associations between VDR 
expression and survival in patients with advanced disease as 
has been demonstrated for other cancer sites, however given 
the limited expected survival within this group of patients it 
may be difficult to detect significant benefits [34]. 
In conclusion, in this Northern Irish population, 
patients with higher VDR expression in oesophageal 
adenocarcinoma have a more favourable prognosis. 
However, further work is needed to validate these findings 
and define the role of VDR in the aetiology, management 
and progression of oesophageal adenocarcinoma. 
MATERIALS AND METHODS
This study was performed and reported in line with 
the REMARK guidelines [35].
Patient selection
In this population-representative study, all patients 
in Northern Ireland who underwent neoadjuvant 
chemotherapy followed by surgical resection for 
oesophageal adenocarcinoma between the 1st January 2004 
and the 31st December 2012 were included. There were 
158 formalin-fixed paraffin embedded (FFPE) oesophageal 
adenocarcinoma resection specimens collected from the 
Northern Ireland Cancer Centre. Of these, slides with 
tumour which could be scored and matched clinical 
information was available for 137 patients. Seven patients 
were excluded from further analysis, as two were staged 
as T0 disease, one had metastatic disease, and tissue 
microarray (TMA) cores were unable to be scored for 
VDR expression for four patients, leaving 130 patients for 
inclusion in our final analysis. Figure 1 summarises the 
indications for exclusion from this study.
Clinical data 
Clinical data and information on study outcomes 
up until 31st December 2014 was retrieved via 
patient note review at the Northern Ireland Cancer 
Centre.  Information included age at diagnosis, date 
of diagnosis, date of surgery, patient sex, smoking 
and alcohol status. Pathology reports were reviewed 
for tumour characteristics including tumour location, 
presence of lymphovascular invasion, circumferential 
resection margin status, tumour differentiation and 
TNM stage. Tumour location was divided into lower 
third of oesophagus (greater than 5 cm proximal to the 
oesophagogastric junction), Siewert 1 (within 1–5 cm 
above the oesophagogastric junction), Siewert 2 (within 
1 cm above and 2 cm below the oesophagogastric 
junction) and Siewert 3 (2–5 cm below the 
oesophagogastric junction) [36]. Pathological staging was 
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defined according to International Union Against Cancer 
(UICC) TNM staging, 7th edition [37]. Finally, the date 
and cause of death were recorded, where applicable. 
Construction of tissue microarrays 
A FFPE tissue block was selected from each resection 
specimen and three 1mm cores of tumour were embedded 
in a paraffin block using the Beecher Manual Arrayer®. 
Immunohistochemistry staining and scoring
Immunohistochemical analysis was performed 
within the NI-Molecular Pathology Laboratory (NI-MPL) 
at Queen’s University Belfast, following approval by the 
Northern Ireland Biobank (study number NIB15-0176). 
Slides were immunostained on a Ventana BenchMark fully 
automated immunostainer, with a previously validated 
rabbit monoclonal VDR antibody (cell signalling-clone 
number D2K6W:  1/100, pre-treatment CC1 32 minutes, 
Optiview detection without amplification) to enable VDR 
expression to be identified and then scanned on an Aperio 
AT2 scanner, and viewed as digital images on Xplore 
(PathXL). 
Biomarker expression was evaluated by a trainee 
pathologist (JT) and an independent observer (surgical 
registrar, SMcC), who were both blinded to clinical 
data. This process was carried out following the training 
and guidance of an expert gastrointestinal pathologist 
(DMcM). The staining intensity from each tissue section 
was assessed along with the percentage of tumour cells 
staining positive and a final agreement on discordant 
results was made. Scoring was based on intensity (0 = no 
staining, 1 = weak, 2 = moderate and 3 = strong staining 
observed) and this was multiplied with the percentage 
of tumour cells staining positive to give an H-score 
between 0 and 300. Examples of these different grades of 
staining are demonstrated in Figure 2. Different methods 
for evaluating the VDR expression are reported in the 
literature and may contribute to different results. A range 
of these methods are displayed in Table 4.
Statistical analysis
Median and maximum H-scores for VDR expression 
across the triplicate tumour cores were generated for 
each patient, to explore if there was an association with 
outcomes. Following evaluation of histograms, the median 
and maximum H-scores were used to create groupings 
of both high/low VDR expression and tertiles of high/
medium/low VDR expression, although the distributions 
in the histograms did appear to favour the latter method. 
Primary analysis evaluated the distribution based on 
the maximum H-score (which may be more clinically 
relevant) from the triplicate cores in TMAs, and median 
H-scores (which may be less subject to sampling errors) 
were evaluated in secondary analysis. 
Patient demographics and tumour characteristics 
according to tumour VDR status were compared using chi-
squared tests. Outcomes studied included the impact of 
VDR expression across tertiles on overall survival (death 
from any cause) and cancer-specific survival (death from 
Figure 1: Flow chart demonstrating reasons for patient exclusion from study.
Oncotarget34354www.oncotarget.com
Figure 2: (A) no staining [intensity 0]; (B) weak staining [intensity 1]; (C) moderate staining [intensity 2]; (D) strong staining [intensity 3].
Table 4:  Different methods of calculating the VDR expression in other studies
Study author Type of cancer Method of staining for VDR
Method of scoring 
grade of staining
Method of scoring 
percentage of cells 
staining positive
Description of how the 
overall score and cut off 
points were calculated
Our study Oesophageal 
adenocarcinoma
Rabbit monoclonal VDR 
antibody
0-no staining
1-Weak 
2-Moderate
3-Strong 
Percentage of tumour 
cells staining positive
Grade multiplied by 
percentage to give H-score 
between 0–300
Zhou et al. [14] Oesophageal 
adenocarcinoma
Mouse mono-clonal 
anti-VDR antibody
0-no staining
1+Weak 
2+Moderate
3+Strong
>or< than 10% of tumour 
cells staining positive 
If 10% or more of cells 
stained 2+ or 3+ was deemed 
to have high expression
Wang et al. [9] Pancreatic 
adenocarcinoma
3,3 diaminobenzidine 
with western blot
0-no staining
1-Weak 
2-Moderate
3-Strong
Score 0 (<5%)
Score 1 (6–25%)
Score 2 (26–50%)
Score 3 (51–75%)
Score 4 (76–100%)
Grade score multiplied by 
percentage score. Maximum 
of 12 with <4 low expression 
and 4 or greater high 
expression
Seubwai et al. 
[22]
Cholangiocarcinoma Rat anti-VDR 
monoclonal antibody
Did not score grade 0 = negative
1+ (1%–25%)
2+ (26%–50%)
3+ (>50%)
Patients were grouped into 
one of the four groups as per 
the percentage of staining. 
Analysis often involved 
presence versus absence of 
VDR
Ditsch et al. 
[10]
Breast Cancer Vitamin D antibody 
(monoclonal clone 2F4 
isotype IgG2a, AbD 
Serotec)
0-no staining
1-Weak 
2-Moderate
3-Strong
0 = negative
1 = <10%
2 = 11%–50%
3 = 51%–80%
4 =>81%
Grade was multiplied by 
percenatage that stained 
positive with a maximum 
score of 12. 0–1 indicated no 
staining, 2–4 was moderate 
staining and 6–12 was high 
staining
Brozna et al. 
[11]
Cutaneous melanoma Monoclonal antibodies 
(clone 97A, Abcam Inc, 
Cambridge)
0-no staining
1-Weak 
2-Moderate
3-Strong
Did not score percentage Cut off points were as per 
the three levels of grading
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oesophageal adenocarcinoma). Comparison between VDR 
status and prognosis was evaluated using Cox proportional 
hazards regression models for unadjusted and adjusted 
results. The variables included in the adjusted analysis 
were age at diagnosis, gender, tumour nodal status, 
circumferential resection margin, tumour differentiation, 
lymphovascular invasion, smoking status and tumour 
location. Sensitivity analysis was performed for junctional 
tumours separately. Stata version 14.2 (College Station, 
TX, USA) was used for statistical analysis.
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